We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 14, Issue 2, Pages 127-130
Publisher
Informa UK Limited
Online
2014-01-13
DOI
10.1586/14737175.2014.874947
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Switching from natalizumab to fingolimod: an observational study
- (2013) A. P. Sempere et al. ACTA NEUROLOGICA SCANDINAVICA
- Natalizumab adverse events are rare in patients with multiple sclerosis
- (2013) Yára Dadalti Fragoso et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
- (2013) Claudio Gobbi et al. BMC Neurology
- Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis
- (2013) Paul L. McCormack DRUGS
- Update on Therapeutic Options for Multiple Sclerosis
- (2013) Matthew McCoyd NEUROLOGIC CLINICS
- Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
- (2012) S. Rossi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Multiple sclerosis
- (2012) Alyssa Nylander et al. JOURNAL OF CLINICAL INVESTIGATION
- Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
- (2012) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
- (2012) L Daelman et al. Multiple Sclerosis Journal
- Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
- (2012) Sebastian Jander et al. Multiple Sclerosis Journal
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
- (2012) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Simultaneous Pml-Iris After Discontinuation of Natalizumab in A Patient With MS
- (2012) S. Marousi et al. NEUROLOGY
- Severe relapses under fingolimod treatment prescribed after natalizumab
- (2012) D. Centonze et al. NEUROLOGY
- Lethal multiple sclerosis relapse after natalizumab withdrawal
- (2012) V. Rigau et al. NEUROLOGY
- Best practice in the use of natalizumab in multiple sclerosis
- (2012) Óscar Fernández Therapeutic Advances in Neurological Disorders
- Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study
- (2011) G. Borriello et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinical and Radiological Disease Reactivation After Cessation of Long-Term Therapy With Natalizumab
- (2011) Annette Baumgartner et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study
- (2011) María José Magraner et al. JOURNAL OF NEUROLOGY
- De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
- (2011) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Early onset of natalizumab-related progressive multifocal leukoencephalopathy
- (2011) A Damasceno et al. Multiple Sclerosis Journal
- Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse
- (2011) C Papeix et al. Multiple Sclerosis Journal
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
- (2010) Joseph R. Berger et al. ANNALS OF NEUROLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Observations during an elective interruption of natalizumab treatment: a post-marketing study
- (2010) Giovanna Borriello et al. Multiple Sclerosis Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started